Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human QEL-005 in diffuse cutaneous systemic sclerosis and difficult-to-treat rheumatoid arthritis
2025-523971-46-00Phase 2Authorised
- Sponsor
- Quell Therapeutics
- Start
- Sep 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Regulatory T Cells (Tregs) → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 3
01
Overview
Phase 2, open-label trial of QEL-005 in systemic sclerosis (SSc) and rheumatoid arthritis (RA) (2 cohorts), sponsored by Quell Therapeutics. Planned start Sep 2026; status: authorised.
02
Drugs
QEL-005
03
Conditions
systemic sclerosis (SSc)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2025-523971-46-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523971-46-00.